Adjuvant Docetaxel for Node-Positive Breast Cancer

• Published in: The New England journal of medicine Vol. 352; no. 22; pp. 2302 - 2313
• Main Authors: Martin, Miguel, Pienkowski, Tadeusz, Mackey, John, Pawlicki, Marek, Guastalla, Jean-Paul, Weaver, Charles, Tomiak, Eva, Al-Tweigeri, Taher, Chap, Linnea, Juhos, Eva, Guevin, Raymond, Howell, Anthony, Fornander, Tommy, Hainsworth, John, Coleman, Robert, Vinholes, Jeferson, Modiano, Manuel, Pinter, Tamas, Tang, Shou C, Colwell, Bruce, Prady, Catherine, Provencher, Louise, Walde, David, Rodriguez-Lescure, Alvaro, Hugh, Judith, Loret, Camille, Rupin, Matthieu, Blitz, Sandra, Jacobs, Philip, Murawsky, Michael, Riva, Alessandro, Vogel, Charles
• Format: Journal Article
• Language: English
• Published: Boston, MA Massachusetts Medical Society 02.06.2005
• Subjects: Adult; Aged; Antineoplastic Agents, Phytogenic - adverse effects; Antineoplastic Agents, Phytogenic - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - mortality; Breast Neoplasms - surgery; Cancer therapies; Chemotherapy; Chemotherapy, Adjuvant; Cyclophosphamide - administration & dosage; Cyclophosphamide - adverse effects; Disease-Free Survival; Doxorubicin - administration & dosage; Doxorubicin - adverse effects; Female; Fluorouracil - administration & dosage; Fluorouracil - adverse effects; Follow-Up Studies; General aspects; Humans; Lymphatic Metastasis; Medical sciences; Medicin och hälsovetenskap; Middle Aged; Quality of Life; Survival Analysis; Taxoids - adverse effects; Taxoids - therapeutic use; Womens health; Antineoplastic agent; Medicine; Mammary gland diseases; Taxane derivatives; Docetaxel; Node; Adjuvant; Breast cancer; Mammary gland; Malignant tumor; Antimitotic
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa043681

This randomized trial included almost 1500 women with breast cancer and positive axillary nodes and compared treatment with doxorubicin and cyclophosphamide combined with either fluorouracil or docetaxel. The rates of disease-free and overall survival were significantly higher among women in the docetaxel group. This trial compared treatment with doxorubicin and cyclophosphamide combined with either fluorouracil or docetaxel. The rates of disease-free and overall survival were significantly higher among women in the docetaxel group. Adjuvant chemotherapy for breast cancer has undergone a major change over the past two decades. Chemotherapy with a regimen that includes an anthracycline or a combination of cyclophosphamide, methotrexate, and fluorouracil significantly decreases the risks of disease recurrence and death among women with early-stage breast cancer. 1 The overview analysis of the Early Breast Cancer Trialists' Collaborative Group demonstrated that, as compared with standard treatment with cyclophosphamide, methotrexate, and fluorouracil, regimens that contained doxorubicin or epirubicin reduced the annual risk of recurrence of breast cancer by 12 percent and the annual risk of death by 11 percent. Rates of disease-free and . . .